Persons with dispensed medicines; background; 2006-2020
| Sex | Age | Background and generation | Medicine group (ATC) | Periods | Persons with medicines, relative (%) |
|---|---|---|---|---|---|
| Total male and female | Total age | Total background and generation | Total | 2020 | 62.80 |
| Total male and female | Total age | Total background and generation | A Alimentary tract and metabolism | 2020 | 24.24 |
| Total male and female | Total age | Total background and generation | A01 Stomatological preparations | 2020 | 0.25 |
| Total male and female | Total age | Total background and generation | A01A Stomatological preparations | 2020 | 0.25 |
| Total male and female | Total age | Total background and generation | A02 Drugs for acid related disorders | 2020 | 12.76 |
| Total male and female | Total age | Total background and generation | A02A Antacids | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A02B Drugs for peptic ulcer and gord | 2020 | 12.76 |
| Total male and female | Total age | Total background and generation | A02X Oth. drugs for acid related disord. | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A03 Drugs for funct.gastrointest.disord. | 2020 | 2.09 |
| Total male and female | Total age | Total background and generation | A03A Drugs for functional bowel disord. | 2020 | 0.53 |
| Total male and female | Total age | Total background and generation | A03B Belladonna and derivatives, plain | 2020 | 0.03 |
| Total male and female | Total age | Total background and generation | A03C Antispasmodics with psycholeptics | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A03D Antispasmodics with analgesics | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A03E Antispasmodics and anticholinergics | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A03F Propulsives | 2020 | 1.59 |
| Total male and female | Total age | Total background and generation | A04 Antiemetics and antinauseants | 2020 | 0.46 |
| Total male and female | Total age | Total background and generation | A04A Antiemetics and antinauseants | 2020 | 0.46 |
| Total male and female | Total age | Total background and generation | A05 Bile and liver therapy | 2020 | 0.09 |
| Total male and female | Total age | Total background and generation | A05A Bile therapy | 2020 | 0.09 |
| Total male and female | Total age | Total background and generation | A05B Liver therapy, lipotropics | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A05C Bile therapy drugs and lipotropics | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A06 Laxatives | 2020 | 8.03 |
| Total male and female | Total age | Total background and generation | A06A Laxatives | 2020 | 8.03 |
| Total male and female | Total age | Total background and generation | A07 Anti diarr/intest/infl/infect.agents | 2020 | 1.20 |
| Total male and female | Total age | Total background and generation | A07A Intestinal antiinfectives | 2020 | 0.60 |
| Total male and female | Total age | Total background and generation | A07B Intestinal adsorbents | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A07C Electrolytes with carbohydrates | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A07D Antipropulsives | 2020 | 0.13 |
| Total male and female | Total age | Total background and generation | A07E Intestinal antiinflammatory agents | 2020 | 0.49 |
| Total male and female | Total age | Total background and generation | A07F Antidiarrheal microorganisms | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A07X Other antidiarrheals | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A08 Antiobesity prep. excl.diet products | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A08A Antiobesity prep.excl.diet products | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A09 Digestives, incl. enzymes | 2020 | 0.11 |
| Total male and female | Total age | Total background and generation | A09A Digestives, incl. enzymes | 2020 | 0.11 |
| Total male and female | Total age | Total background and generation | A10 Drugs used in diabetes | 2020 | 4.65 |
| Total male and female | Total age | Total background and generation | A10A Insulins and analogues | 2020 | 1.59 |
| Total male and female | Total age | Total background and generation | A10B Blood glucose lowering drugs, excl. | 2020 | 4.04 |
| Total male and female | Total age | Total background and generation | A10X Other drugs used in diabetes | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A11 Vitamins | 2020 | 5.27 |
| Total male and female | Total age | Total background and generation | A11A Multivitamins, combinations | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A11B Multivitamins, plain | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A11C Vit A and D, incl.combin.of the two | 2020 | 5.26 |
| Total male and female | Total age | Total background and generation | A11D Vitamin B1,and with vit. B6 and B12 | 2020 | 0.01 |
| Total male and female | Total age | Total background and generation | A11E Vitamin B-complex, incl. combinat. | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A11G Ascorbic acid (vitamin C) + combin. | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A11H Other plain vitamin preparations | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A11J Other vitamin products + combinat. | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A12 Mineral supplements | 2020 | 3.26 |
| Total male and female | Total age | Total background and generation | A12A Calcium | 2020 | 3.11 |
| Total male and female | Total age | Total background and generation | A12B Potassium | 2020 | 0.17 |
| Total male and female | Total age | Total background and generation | A12C Other mineral supplements | 2020 | 0.04 |
| Total male and female | Total age | Total background and generation | A13 Tonics | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A13A Tonics | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A14 Anabolic agents for systemic use | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A14A Anabolic steroids | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A14B Other anabolic agents | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A15 Appetite stimulants | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | A16 Other aliment.tract/metabol.products | 2020 | 0.02 |
| Total male and female | Total age | Total background and generation | A16A Oth.aliment.tract and metabol.prod. | 2020 | 0.02 |
| Total male and female | Total age | Total background and generation | B Blood and blood forming organs | 2020 | 12.85 |
| Total male and female | Total age | Total background and generation | B01 Antithrombotic agents | 2020 | 10.43 |
| Total male and female | Total age | Total background and generation | B01A Antithrombotic agents | 2020 | 10.43 |
| Total male and female | Total age | Total background and generation | B02 Antihemorrhagics | 2020 | 0.25 |
| Total male and female | Total age | Total background and generation | B02A Antifibrinolytics | 2020 | 0.16 |
| Total male and female | Total age | Total background and generation | B02B Vitamin k and other hemostatics | 2020 | 0.09 |
| Total male and female | Total age | Total background and generation | B03 Antianemic preparations | 2020 | 3.19 |
| Total male and female | Total age | Total background and generation | B03A Iron preparations | 2020 | 1.59 |
| Total male and female | Total age | Total background and generation | B03B Vitamin B12 and folic acid | 2020 | 1.72 |
| Total male and female | Total age | Total background and generation | B03X Other antianemic preparations | 2020 | 0.08 |
| Total male and female | Total age | Total background and generation | B05 Blood substitutes / perfus.solutions | 2020 | 0.26 |
| Total male and female | Total age | Total background and generation | B05A Blood and related products | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | B05B Intravenous solutions | 2020 | 0.25 |
| Total male and female | Total age | Total background and generation | B05C Irrigating solutions | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | B05D Peritoneal dialytics | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | B05X Intravenous solution additives | 2020 | 0.01 |
| Total male and female | Total age | Total background and generation | B05Z Hemodialytics and hemofiltrates | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | B06 Other hematological agents | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | B06A Other hematological agents | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | C Cardiovascular system | 2020 | 21.18 |
| Total male and female | Total age | Total background and generation | C01 Cardiac therapy | 2020 | 2.46 |
| Total male and female | Total age | Total background and generation | C01A Cardiac glycosides | 2020 | 0.46 |
| Total male and female | Total age | Total background and generation | C01B Antiarrhythmics, class I and III | 2020 | 0.39 |
| Total male and female | Total age | Total background and generation | C01C Cardiac stimulants excl. glycosides | 2020 | 0.30 |
| Total male and female | Total age | Total background and generation | C01D Vasodilators used in card. diseases | 2020 | 1.40 |
| Total male and female | Total age | Total background and generation | C01E Other cardiac preparations | 2020 | 0.07 |
| Total male and female | Total age | Total background and generation | C02 Antihypertensives | 2020 | 0.32 |
| Total male and female | Total age | Total background and generation | C02A Antiadren.agents, centrally acting | 2020 | 0.06 |
| Total male and female | Total age | Total background and generation | C02B Antiadren.agents, ganglion-blocking | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | C02C Antiadren.agents, peripher. acting | 2020 | 0.24 |
| Total male and female | Total age | Total background and generation | C02D Arteriolar smooth muscle agents | 2020 | 0.01 |
| Total male and female | Total age | Total background and generation | C02K Other antihypertensives | 2020 | 0.02 |
| Total male and female | Total age | Total background and generation | C02L Antihypertensives/diuretics combin. | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | C02N Combinations of antihypertensives.. | 2020 | 0.00 |
| Total male and female | Total age | Total background and generation | C03 Diuretics | 2020 | 6.18 |
| Total male and female | Total age | Total background and generation | C03A Low-ceiling diuretics, thiazides | 2020 | 3.44 |
| Total male and female | Total age | Total background and generation | C03B Low-ceiling diuret.,excl. thiazides | 2020 | 0.39 |
| Total male and female | Total age | Total background and generation | C03C High-ceiling diuretics | 2020 | 2.02 |
| Total male and female | Total age | Total background and generation | C03D Potassium-sparing agents | 2020 | 1.01 |
| Total male and female | Total age | Total background and generation | C03E Diuretics/potassium-sparing agents | 2020 | 0.18 |
| Source: CBS. | |||||
Table explanation
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Basic Registration of Persons (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
CBS is switching to a new population classification by origin. Greater emphasis will be placed on where a person was born and less on where their parents were born. The term ‘migration background’ will no longer be used in this regard. The main categories western/non-western will be replaced by categories based on continents and a few countries that share a specific migration history with the Netherlands. This classification will gradually been introduced in tables and publications with population by origin.
Data are broken down by medicine group, background, generation, age and sex.
Data available from 2006 to 2020.
Status of the figures:
All figures are definite.
Changes as of 14 December, 2022:
Figures for 2020 have been made final without change and the table has been stopped due to the introduction of the new classification of population by origin.
When will new figures be published?
Not applicable, the table has been stopped. This table will be replaced by the new table 'Persons with dispensed medicines; origin', see chapter 3.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.